Pfizer's second biosimilar of J&J's Remicade wins U.S. FDA approval
December 13, 2017 at 20:09 PM EST
Dec 13 (Reuters) - The U.S. Food and Drug Administration approved Pfizer Inc's second biosimilar to Johnson & Johnson's blockbuster rheumatoid arthritis drug, Remicade, the company said on Wednesday.
